|
By BioMedReports.Com
|
|
Tuesday, 24 December 2019 03:31 |
 Shares of Q BioMed (OTCMKTS: QBIO) have been rising steadily during the last few sessions after former Wall Street Journal All Star Analyst Theodore R. O’Neill, IRC initiated sponsored coverage on the emerging commercial stage biotech developer.
|
|
Read more...
|
|
By BioMedReports.Com
|
|
Friday, 15 March 2019 03:43 |
 Predictions have been made by an independent Commission on the Future of Surgery which was set up by the UK’s Royal College of Surgeons that a raft of state-of-the-art technology is going to transform the way medical surgery is carried out.
|
|
Read more...
|
|
By M.E.Garza
|
|
Thursday, 07 March 2019 03:20 |
Q BioMed (OTCQB:QBIO), has been getting attention from biotech investors and pharma industry publications for its “upside down” biotech business model. The company expects to continue making strides in developing their product offerings and appears well positioned to generate revenue in 2019 and beyond.
|
|
Read more...
|
|
By BioMedReports.Com
|
|
Wednesday, 06 March 2019 00:52 |
 Over the years, Investors have seen biotech companies as risky yet very profitable ventures. Mostly, this is due to the cutthroat competition where these companies have to come up with the best innovations in the healthcare department.
|
|
Read more...
|
|
By Staff and Wire Reports
|
|
Friday, 08 February 2019 02:51 |
 Q BioMed (OTCMKTS: QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally.
|
|
Read more...
|
|
By Staff and Wire Reports
|
|
Wednesday, 06 February 2019 00:00 |
 Shares of MacroGenics, Inc. (NASDAQ: MGNX) soared after the company announced positive results from SOPHIA, the Company’s Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients.
|
|
Read more...
|
|
By M.E.Garza
|
|
Thursday, 17 January 2019 13:15 |
 An anticipated key FDA decision is set to transform Q BioMed (OTCMKTS: QBIO) from a biotech developer to a revenue generating manufacturer in what may be record time. That imminent event is already attracting interest from traders and investors, but a game changing plan revealed by the CEO may be an even stronger reason to focus on this emerging biotechnology accelerator.
|
|
Read more...
|
|
By M.E.Garza
|
|
Tuesday, 08 January 2019 02:47 |
|
These three biotechs have kicked off the new year in a very bullish way, but where do things go from here for Novavax, Q Biomed and Axsome Therapeutics?
|
|
Read more...
|
|
By M.E.Garza
|
|
Friday, 29 June 2018 00:04 |
 Shares of Transenterix Inc (NYSE: TRXC) and Sophiris Bio (NASDAQ:SPHS) have seen record numbers in trading volume this week, yet despite solid footing, both firms have seen their share prices rocked by unexpected news.
|
|
Read more...
|
|
By Staff and Wire Reports
|
|
Wednesday, 21 September 2016 11:38 |
 Q&A with Brian Murphy MD, CEO/CMO, NEMUS Bioscience
Humans produce a range of chemical compounds called cannabinoids that keep the human body stable by binding to receptors on cell membranes and controlling the release of chemical messengers that regulate everything from how humans experience pain to our moods. While most people's endocannabinoid systems naturally help maintain a state of homeostasis, or stability, conditions such as multiple sclerosis or treatments for diseases like cancer can throw off that balance. Introducing cannabinoids made outside the body might help. Marijuana also contains cannabinoids – at least 66 of them.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 1 of 56 |
